Antibody engineering by sequence comparison finds safe modification sites to preserve antigen binding.
The method identifies substitutable amino-acid positions in a “parent” antibody by comparing its sequence to multiple related antibodies that bind the same antigen, flagging sites likely to tolerate changes. This reduces binding loss risk by targeting changeable residues rather than random mutagenesis, effectively narrowing the search from many positions to only “safe” candidates. Before expiration, using the patented approach for selecting modification sites could require licensing from the assignee for antibody optimization workflows.
Build next-gen therapeutic antibody variants by using safe-site mapping to speed affinity, stability, and humanization testing.
The invention provides a method for identifying positions of an antibody that can be modified without significantly reducing the binding activity of the antibody. In many embodiments, the method involves identifying a substitutable position in a parent antibody by comparing its amino acid sequence to the amino acid sequences of a number of related antibodies that each bind to the same antigen as the parent antibody.
Post a problem you're solving with this technology and connect with founders, investors, and researchers.